Castle Biosciences (CSTL) Competitors

$20.15 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$20.14 -0.01 (-0.05%)

As of 05/22/2026 07:12 PM Eastern

CSTL vs. HTFL, DFTX, PGNY, SGRY, and ADUS

Should you buy Castle Biosciences stock or one of its competitors? MarketBeat compares Castle Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Castle Biosciences include Heartflow (HTFL), Definium Therapeutics (DFTX), Progyny (PGNY), Surgery Partners (SGRY), and Addus HomeCare (ADUS). These companies are all part of the "healthcare" industry.

How does Castle Biosciences compare to Heartflow?

Heartflow (NASDAQ:HTFL) and Castle Biosciences (NASDAQ:CSTL) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, media sentiment and dividends.

92.6% of Castle Biosciences shares are owned by institutional investors. 7.7% of Heartflow shares are owned by insiders. Comparatively, 6.1% of Castle Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Castle Biosciences had 4 more articles in the media than Heartflow. MarketBeat recorded 6 mentions for Castle Biosciences and 2 mentions for Heartflow. Heartflow's average media sentiment score of -0.03 beat Castle Biosciences' score of -0.59 indicating that Heartflow is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heartflow	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Castle Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Castle Biosciences has a net margin of -3.78% compared to Heartflow's net margin of -58.42%. Heartflow's return on equity of 0.00% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heartflow	-58.42%	N/A	-20.02%
Castle Biosciences	-3.78%	-2.77%	-2.30%

Castle Biosciences has higher revenue and earnings than Heartflow. Castle Biosciences is trading at a lower price-to-earnings ratio than Heartflow, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heartflow	$176.03M	14.45	-$116.79M	-$3.11	N/A
Castle Biosciences	$344.23M	1.78	-$24.16M	-$0.44	N/A

Heartflow presently has a consensus price target of $37.00, indicating a potential upside of 25.47%. Castle Biosciences has a consensus price target of $45.33, indicating a potential upside of 124.98%. Given Castle Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Castle Biosciences is more favorable than Heartflow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heartflow	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Castle Biosciences	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

Castle Biosciences beats Heartflow on 11 of the 16 factors compared between the two stocks.

How does Castle Biosciences compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Castle Biosciences (NASDAQ:CSTL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

27.9% of Definium Therapeutics shares are owned by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are owned by institutional investors. 2.3% of Definium Therapeutics shares are owned by insiders. Comparatively, 6.1% of Castle Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Definium Therapeutics had 2 more articles in the media than Castle Biosciences. MarketBeat recorded 8 mentions for Definium Therapeutics and 6 mentions for Castle Biosciences. Definium Therapeutics' average media sentiment score of -0.08 beat Castle Biosciences' score of -0.59 indicating that Definium Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Castle Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Definium Therapeutics has a net margin of 0.00% compared to Castle Biosciences' net margin of -3.78%. Castle Biosciences' return on equity of -2.77% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-100.30%	-69.22%
Castle Biosciences	-3.78%	-2.77%	-2.30%

Definium Therapeutics has a beta of 2.37, suggesting that its share price is 137% more volatile than the broader market. Comparatively, Castle Biosciences has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market.

Castle Biosciences has higher revenue and earnings than Definium Therapeutics. Castle Biosciences is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A
Castle Biosciences	$344.23M	1.78	-$24.16M	-$0.44	N/A

Definium Therapeutics currently has a consensus target price of $37.92, suggesting a potential upside of 68.55%. Castle Biosciences has a consensus target price of $45.33, suggesting a potential upside of 124.98%. Given Castle Biosciences' higher possible upside, analysts plainly believe Castle Biosciences is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Castle Biosciences	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

Definium Therapeutics and Castle Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Castle Biosciences compare to Progyny?

Progyny (NASDAQ:PGNY) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Progyny has a net margin of 5.23% compared to Castle Biosciences' net margin of -3.78%. Progyny's return on equity of 13.34% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	5.23%	13.34%	9.03%
Castle Biosciences	-3.78%	-2.77%	-2.30%

Progyny has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	1.51	$58.52M	$0.77	32.31
Castle Biosciences	$344.23M	1.78	-$24.16M	-$0.44	N/A

Progyny has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Castle Biosciences has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

94.9% of Progyny shares are held by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are held by institutional investors. 9.9% of Progyny shares are held by insiders. Comparatively, 6.1% of Castle Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Progyny currently has a consensus target price of $29.55, indicating a potential upside of 18.75%. Castle Biosciences has a consensus target price of $45.33, indicating a potential upside of 124.98%. Given Castle Biosciences' higher possible upside, analysts plainly believe Castle Biosciences is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Castle Biosciences	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Progyny had 2 more articles in the media than Castle Biosciences. MarketBeat recorded 8 mentions for Progyny and 6 mentions for Castle Biosciences. Progyny's average media sentiment score of 0.24 beat Castle Biosciences' score of -0.59 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Castle Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Progyny beats Castle Biosciences on 13 of the 16 factors compared between the two stocks.

How does Castle Biosciences compare to Surgery Partners?

Surgery Partners (NASDAQ:SGRY) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Surgery Partners has a net margin of -2.28% compared to Castle Biosciences' net margin of -3.78%. Surgery Partners' return on equity of 1.04% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surgery Partners	-2.28%	1.04%	0.41%
Castle Biosciences	-3.78%	-2.77%	-2.30%

Surgery Partners has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market. Comparatively, Castle Biosciences has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

Castle Biosciences has lower revenue, but higher earnings than Surgery Partners. Castle Biosciences is trading at a lower price-to-earnings ratio than Surgery Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surgery Partners	$3.31B	0.53	-$77.90M	-$0.60	N/A
Castle Biosciences	$344.23M	1.78	-$24.16M	-$0.44	N/A

Surgery Partners presently has a consensus price target of $22.18, indicating a potential upside of 65.54%. Castle Biosciences has a consensus price target of $45.33, indicating a potential upside of 124.98%. Given Castle Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Castle Biosciences is more favorable than Surgery Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surgery Partners	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Castle Biosciences	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

92.6% of Castle Biosciences shares are held by institutional investors. 2.7% of Surgery Partners shares are held by company insiders. Comparatively, 6.1% of Castle Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Castle Biosciences had 2 more articles in the media than Surgery Partners. MarketBeat recorded 6 mentions for Castle Biosciences and 4 mentions for Surgery Partners. Surgery Partners' average media sentiment score of 0.34 beat Castle Biosciences' score of -0.59 indicating that Surgery Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surgery Partners	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Castle Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Castle Biosciences beats Surgery Partners on 9 of the 17 factors compared between the two stocks.

How does Castle Biosciences compare to Addus HomeCare?

Addus HomeCare (NASDAQ:ADUS) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

Addus HomeCare has higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addus HomeCare	$1.42B	1.22	$95.91M	$5.41	17.13
Castle Biosciences	$344.23M	1.78	-$24.16M	-$0.44	N/A

Addus HomeCare has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market. Comparatively, Castle Biosciences has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

95.4% of Addus HomeCare shares are held by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are held by institutional investors. 4.5% of Addus HomeCare shares are held by insiders. Comparatively, 6.1% of Castle Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Addus HomeCare had 9 more articles in the media than Castle Biosciences. MarketBeat recorded 15 mentions for Addus HomeCare and 6 mentions for Castle Biosciences. Addus HomeCare's average media sentiment score of 0.75 beat Castle Biosciences' score of -0.59 indicating that Addus HomeCare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Addus HomeCare	8 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Castle Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Addus HomeCare has a net margin of 6.89% compared to Castle Biosciences' net margin of -3.78%. Addus HomeCare's return on equity of 9.80% beat Castle Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addus HomeCare	6.89%	9.80%	7.34%
Castle Biosciences	-3.78%	-2.77%	-2.30%

Addus HomeCare currently has a consensus target price of $131.22, indicating a potential upside of 41.63%. Castle Biosciences has a consensus target price of $45.33, indicating a potential upside of 124.98%. Given Castle Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Castle Biosciences is more favorable than Addus HomeCare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addus HomeCare	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Castle Biosciences	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

Addus HomeCare beats Castle Biosciences on 10 of the 15 factors compared between the two stocks.

Get Castle Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CSTL vs. The Competition

Export

Metric	Castle Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$611.15M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-45.80	18.74	21.21	25.65
Price / Sales	1.78	323.98	554.38	86.31
Price / Cash	18.10	125.17	43.49	56.67
Price / Book	1.32	7.09	10.37	7.14
Net Income	-$24.16M	$24.45M	$3.57B	$335.98M
7 Day Performance	4.95%	6.38%	6.40%	4.15%
1 Month Performance	-17.62%	2.43%	3.53%	2.54%
1 Year Performance	25.16%	62.98%	34.04%	35.06%

Castle Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
CSTL Castle Biosciences	3.3444 of 5 stars	$20.15 flat	$45.33 +125.0%	+25.2%	$611.15M	$344.23M	N/A	540
HTFL Heartflow	3.332 of 5 stars	$25.89 +0.9%	$37.00 +42.9%	N/A	$2.23B	$191.42M	N/A	699
DFTX Definium Therapeutics	2.9572 of 5 stars	$19.91 -2.8%	$37.92 +90.5%	+208.2%	$1.99B	N/A	N/A	40
PGNY Progyny	4.0115 of 5 stars	$24.73 +2.8%	$28.55 +15.4%	+21.2%	$1.93B	$1.29B	32.04	310
SGRY Surgery Partners	3.716 of 5 stars	$13.61 -2.2%	$22.18 +63.0%	-41.2%	$1.79B	$3.31B	N/A	16,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CSTL) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Castle Biosciences (CSTL) Competitors

CSTL vs. HTFL, DFTX, PGNY, SGRY, and ADUS

How does Castle Biosciences compare to Heartflow?

Summary

How does Castle Biosciences compare to Definium Therapeutics?

Summary

How does Castle Biosciences compare to Progyny?

Summary

How does Castle Biosciences compare to Surgery Partners?

Summary

How does Castle Biosciences compare to Addus HomeCare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSTL vs. The Competition

Castle Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Castle Biosciences (CSTL) Competitors

CSTL vs. HTFL, DFTX, PGNY, SGRY, and ADUS

How does Castle Biosciences compare to Heartflow?

Do institutionals and insiders have more ownership in HTFL or CSTL?

Does the media prefer HTFL or CSTL?

Is HTFL or CSTL more profitable?

Which has higher valuation & earnings, HTFL or CSTL?

Do analysts recommend HTFL or CSTL?

Summary

How does Castle Biosciences compare to Definium Therapeutics?

Do institutionals and insiders hold more shares of DFTX or CSTL?

Does the media refer more to DFTX or CSTL?

Is DFTX or CSTL more profitable?

Which has more risk & volatility, DFTX or CSTL?

Which has preferable valuation & earnings, DFTX or CSTL?

Do analysts prefer DFTX or CSTL?

Summary

How does Castle Biosciences compare to Progyny?

Is PGNY or CSTL more profitable?

Which has better valuation & earnings, PGNY or CSTL?

Which has more risk and volatility, PGNY or CSTL?

Do insiders & institutionals believe in PGNY or CSTL?

Do analysts prefer PGNY or CSTL?

Does the media refer more to PGNY or CSTL?

Summary

How does Castle Biosciences compare to Surgery Partners?

Is SGRY or CSTL more profitable?

Which has more volatility and risk, SGRY or CSTL?

Which has higher earnings and valuation, SGRY or CSTL?

Do analysts prefer SGRY or CSTL?

Do institutionals and insiders believe in SGRY or CSTL?

Does the media refer more to SGRY or CSTL?

Summary

How does Castle Biosciences compare to Addus HomeCare?

Which has higher valuation & earnings, ADUS or CSTL?

Which has more volatility and risk, ADUS or CSTL?

Do institutionals & insiders believe in ADUS or CSTL?

Does the media refer more to ADUS or CSTL?

Is ADUS or CSTL more profitable?

Do analysts recommend ADUS or CSTL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSTL vs. The Competition

Castle Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools